Recalled Medicines & supplements – Current GIS Alerts 2026
Found 713 recalled products in the Medicines & supplements category. Check batch numbers, shops, and hazard information.
Common hazards in this category
All recalled products
Soliris
Incorrect vial labeling was found – the phrases “concentrate for solution for infusion”, “for intravenous use”, “dilute before use” were in Slovak and Czech, which may hinder correct administration and a risk to health cannot be excluded. Potential effects: serious administration errors, lack of efficacy or treatment complications.
Bupivacaine and Epinephrine, Bupivacaine-Epinephrine 0,5%,
A change in solution colour from clear to opalescent, brown or yellow was reported. Product with changed colour must not be used and must be discarded; it is a solution for injection. Potential effects: possible toxic action or lack of anaesthetic efficacy, adverse reactions after injection.
Bupivacaine and Epinephrine, Bupivacaine-Epinephrine 0,5%,
The product is a solution for injection; a change in colour from clear to opalescent, brown or yellow may indicate drug degradation; a discoloured product must not be used and must be discarded. Potential effects: lack of efficacy, adverse reactions or complications after administration of a solution of inadequate quality.
DEXAPINI
At the same time, the document stated that “crystallisation of sugar reduces the sugar concentration in the remaining liquid, which may theoretically lead to microbiological contamination.” The GIF indicated a real risk of loss of batch quality, especially after first opening the bottle. Potential effects: possible microbiological contamination of the syrup, risk of infection and lack of safe use.
Veriflo
Negative result of quality tests: non-compliant mean content in the delivered dose between containers for fluticasone propionate and salmeterol and lack of uniformity of the delivered dose; this parameter was deemed critical for the efficacy and safety of product use. Potential effects: impaired disease control, lack of treatment efficacy, or adverse effects related to incorrect dosing.
Liv 52
It was found that the medicinal product documentation was not updated to current European Pharmacopoeia requirements, so the quality of the medicine cannot be properly verified. Potential effects: possible unknown product quality, lack of efficacy or unpredictable adverse reactions.
Liv 52
a medicinal product whose quality cannot be properly verified due to the company’s failure to update the documentation that serves as the reference point for assessing the product’s quality. Potential effects: lack of efficacy, unpredictable adverse reactions.
Pectosol
Leakage from unit packs was found, caused by incompatibility of the bottle with the cap, and an out-of-specification result for the “content in the container” parameter; the impact of this non-compliance on product safety until the end of shelf-life cannot be ruled out. Potential effects: incorrect dosing, reduced efficacy or increased adverse effects.
Pectosol
Leakage from unit packs caused by incompatibility of the bottle with the cap and an out-of-specification result for the “content in the package” parameter were found, which may affect safety of use until the end of shelf life. Potential effects: lack of treatment efficacy, possible irritation or complications if the product becomes contaminated.
Hemkortin-HC
The non-compliance indicated by OMCL may affect the quality of this product and the safety of its use, and therefore a risk to human health from keeping this batch of the medicinal product on the market cannot be excluded. Potential effects: lack of treatment efficacy, possible complications of the underlying disease.
Hemkortin-HC
The non-compliance in the parameter “zinc sulfate monohydrate content” indicated by OMCL may affect product quality and safety of use, and therefore a risk to human health cannot be excluded. Potential effects: lack of treatment efficacy, possible disease complications, skin reactions.
Septogard Plus
Exceeding the upper specification limit for “Related substances. Unspecified Cetylpyridinium impurity” was found, which may affect product quality and safety of use and may pose a risk to human health. Potential effects: impaired drug efficacy, adverse reactions, complications.
Septogard Plus
Exceeding the upper specification limit for the parameter “Related substances. Unspecified Cetylpyridinium impurity”, which may affect product quality and safety of use, therefore a risk to human health cannot be excluded. Potential effects: possible adverse effects and uncertainty regarding the product’s safety and efficacy.
Cefazolin TZF
The presence of brown liquid was found in some vials instead of white or almost white powder, indicating a quality defect of the product and possible impact on the safety of its use. Potential effects: lack of therapeutic efficacy, complications after intravenous or intramuscular administration, and unpredictable adverse reactions.
Cefazolin TZF
The presence of brown liquid was found in some vials instead of white or almost white powder, indicating a serious quality defect that may affect the product’s safety and efficacy. Potential effects: lack of treatment efficacy, infections, severe complications after intravenous administration.
Hemkortin-HC
The product does not meet quality requirements due to a negative test result for the parameter “zinc sulfate monohydrate content”; the level of this substance was found below the lower limit specified in the quality specification. Potential effects: possible decreased treatment efficacy and incomplete drug action.
Monover
A visible large piece of glass of about 1 cm moving inside the vial and glass particles on the walls and neck of the vial of a product administered intravenously were detected. Potential effects: damage to blood vessels, embolism, thrombotic complications, severe systemic complications, life‑threatening conditions.
Monover
A clearly visible large piece of glass and glass particles were confirmed in a vial of the product, and their presence in other vials of the batch cannot be reliably excluded, while the medicine is administered intravenously. Potential effects: embolic complications, vessel damage, severe systemic complications, life-threatening events.
Paracetamol Aflofarm
The above decisions were issued due to a justified suspicion that certain batches of the product did not meet established quality requirements, owing to the inability to obtain a homogeneous suspension and the presence of sediment at the bottom of the bottle despite repeated shaking. Potential effects: possible improper dosing and reduced treatment efficacy.
Osporil
The National Medicines Institute found, in batch ZD033, particles visible to the naked eye in two of twenty inspected vials of the infusion solution. Potential effects: embolism, inflammatory reactions, complications after intravenous administration.
What to do if you bought a recalled product?
If you have purchased any of the products listed above, stop using or consuming them immediately. You can return the product to the store where you bought it for a full refund. Keep the receipt if possible, but most stores will accept returns even without one.